Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29460057 | 1.00 | ALDH1A1 (0.31) | ALDH1A1LMNACES2CES1 | |
| SCHEMBL2993734 | 0.80 | CES2 (0.33) | CES2CES1 | |
| SCHEMBL30502469 | 0.80 | CES2 (0.33) | CES2CES1 | |
| SCHEMBL30952527 | 0.76 | CA1 (0.40) | ALDH1A1LMNACES2CES1 | |
| SCHEMBL1032872 | 0.76 | CA1 (0.40) | ALDH1A1LMNACES2CES1 | |
| SCHEMBL5347272 | 0.76 | CA2 (0.32) | CES2CES1 | |
| SCHEMBL20296440 | 0.74 | ALDH1A1 (0.31) | ALDH1A1CES2CES1 | |
| SCHEMBL29517741 | 0.74 | ALDH1A1 (0.31) | ALDH1A1CES2CES1 | |
| SCHEMBL29956433 | 0.74 | ALDH1A1 (0.34) | ALDH1A1CES2CES1 | |
| SCHEMBL28824845 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195473-B2 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2025-01-14 | — | — | US | disclosed |
| CN-115192577-B | KRAS mutein inhibitors | 北京加科思新药研发有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11787811-B2 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-10-17 | — | — | US | disclosed |
| US-20230011726-A1 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2023-01-12 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-115192577-A | KRAS mutein inhibitors | 北京加科思新药研发有限公司 | 2022-10-18 | — | — | CN | disclosed |
| US-11384087-B1 | — | — | 2022-07-12 | — | — | US | disclosed |
| US-20220213109-A1 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2022-07-07 | — | — | US | disclosed |
| CN-113651814-B | KRAS mutein inhibitors | 北京加科思新药研发有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-114349750-A | KRAS mutein inhibitors | 北京加科思新药研发有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-11180506-B2 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2021-11-23 | — | — | US | disclosed |
| CN-113651814-A | KRAS mutein inhibitors | 北京加科思新药研发有限公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-113454083-A | KRAS mutein inhibitors | 北京加科思新药研发有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-20210292331-A1 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2021-09-23 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230011726-A1 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | ALDH1A1 3978/4885LMNA 3922/4885CES2 4863/4885 |
| US-12195473-B2 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | ALDH1A1 3978/4885LMNA 3922/4885CES2 4863/4885 |
| US-11180506-B2 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | ALDH1A1 3978/4885LMNA 3922/4885CES2 4863/4885 |
| US-11384087-B1 | — | KRAS, NRAS, APC | ALDH1A1 3682/4885LMNA 4247/4885CES2 4821/4885 |
| US-11787811-B2 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | ALDH1A1 3978/4885LMNA 3922/4885CES2 4863/4885 |
| US-20220213109-A1 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | ALDH1A1 3978/4885LMNA 3922/4885CES2 4863/4885 |
| US-20210292331-A1 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | ALDH1A1 3978/4885LMNA 3922/4885CES2 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.